NEW YORK (GenomeWeb News) – Consumer genomics firm GeneLink reported that its first-quarter revenues dropped 45 percent year over year following the sale of its GeneWize Life Sciences subsidiary.

For the three months ended March 31, the Orlando, Fla.-based company posted $771,664 in revenues, down from $1.4 million a year ago, it said in its Form 10-Q filed with the US Securities and Exchange Commission on Monday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.